ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.40173
-0.17%
Brent Oil
84.67
-0.03%
Bitcoin
65,634.81
1.03%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vaxart Inc (VXRT)

  7. Vaxart Inc (VXRT) Noticias

VXRT Vaxart Inc

0.6455
-0.0381 (-5.57%)
Pre Mercado
Última actualización: 04:51:06
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vaxart Inc VXRT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0381 -5.57% 0.6455 04:51:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.6836
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/6/202415:05GLOBEVaxart Provides Business Update
17/6/202405:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/6/202405:03EDGAR2Form 8-K - Current report
13/6/202418:07GLOBEVaxart Announces $40 Million Underwritten Offering of Common..
13/6/202416:26EDGAR2Form 8-K - Current report
13/6/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202415:15GLOBEVaxart Receives BARDA-Funded Project NextGen Award Valued Up..
13/6/202415:07EDGAR2Form 8-K - Current report
12/6/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202415:01GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
13/5/202415:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202415:03EDGAR2Form 8-K - Current report
13/5/202415:01GLOBEVaxart Provides Business Update and Reports First Quarter..
13/5/202406:10IHMARKETNEWSU.S. Futures Climb Amid High Expectations for Inflation..
07/5/202407:00GLOBEVaxart to Host First Quarter 2024 Business Update and..
30/4/202407:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27/3/202407:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20/3/202407:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
14/3/202415:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14/3/202406:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
07/3/202407:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
06/3/202408:23EDGAR2Form 8-K - Current report
06/3/202407:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
29/2/202415:30EDGAR2Form 8-K - Current report
15/2/202415:10EDGAR2Form 8-K - Current report
13/2/202416:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202407:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
02/2/202415:49EDGAR2Form 8-K/A - Current report: [Amend]
19/1/202416:14EDGAR2Form 8-K - Current report
19/1/202415:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19/1/202407:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
16/1/202416:18EDGAR2Form 8-K - Current report
16/1/202408:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
16/1/202408:22GLOBEVaxart, Inc. Announces Management Change
16/1/202408:19EDGAR2Form 8-K - Current report
21/12/202307:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
02/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202315:11EDGAR2Form 8-K - Current report
02/11/202315:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02/11/202307:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26/10/202307:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
23/10/202316:09EDGAR2Form 8-K/A - Current report: [Amend]
23/10/202316:01EDGAR2Form 8-K - Current report
11/10/202307:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21/9/202307:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
06/9/202315:43EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
VXRT
Vaxart
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados